Most metabolic research peptides work from the outside in — targeting receptors on cell surfaces, blocking hormones in circulation, adjusting signals that travel to the mitochondria. MOTS-c works the other direction entirely. It originates inside the mitochondria, travels to the nucleus, and reprograms the cell’s energy-sensing machinery at the source. That retrograde signalling direction — mitochondria to nucleus — is what separates MOTS-c from every other compound in metabolic research and why it has become one of the most studied mitochondrial-derived peptides in modern biology.

MOTS-c is significantly expressed in response to stress or exercise and translocated to the nucleus, where it regulates the expression of stress adaptation-related genes with antioxidant response elements (ARE). It mainly acts through the Folate-AICAR-AMPK pathway, influencing energy metabolism, insulin resistance, inflammatory response, exercise adaptation, and aging-related pathologies. Circulating MOTS-c levels decline measurably with age — tracking alongside reduced mitochondrial function and worsening metabolic flexibility — which is why it has attracted intense interest in both longevity biology and metabolic disease research.

A human clinical trial is now underway. An active first-in-human study (NCT07505745) is testing MOTS-c against placebo in adults with prediabetes over 12 weeks — the most significant development in this research space in 2026. And the FDA’s Pharmacy Compounding Advisory Committee is scheduled to review MOTS-c in July 2026 for obesity and osteoporosis applications under Section 503A.

Get research-grade MOTS-c from PeptideNexusLab — 5mg and 10mg vials, ≥99% purity, COA included, fast global shipping.

What Is MOTS-c?

MOTS-c — Mitochondrial Open Reading Frame of the 12S rRNA Type-c — is a 16-amino acid peptide encoded not by nuclear DNA like most proteins, but by the mitochondrial genome itself. Its full amino acid sequence is MRWQEMGYIFYPRKLR.

Its discovery in 2015 by researchers led by Changhan Lee at the University of Southern California redefined what mitochondria do. They had long been understood as the cell’s energy factories. MOTS-c revealed they are also signalling organs — capable of encoding bioactive peptides that travel to the nucleus and directly reprogram gene expression in response to metabolic stress. Because of this behaviour, MOTS-c has been called a “mitochondrial hormone” and a “mitokine” — circulating in blood and detected across multiple tissues including skeletal muscle.

MOTS-c expression is activated by stress and exercise, while its levels decrease measurably with aging. This decline-with-age signature — combined with its central role in energy homeostasis — is what has made MOTS-c one of the most investigated compounds at the intersection of metabolic disease, exercise physiology, and longevity biology.

Mechanism of Action

The Folate-AICAR-AMPK pathway — the core mechanism

MOTS-c activates AMPK by inhibiting the de novo purine synthesis pathway, reducing methyleneTHF availability and driving AICAR accumulation. AICAR is a well-established AMPK activator. This chain is the mechanistic foundation of MOTS-c’s metabolic effects — and understanding it is essential for designing meaningful research protocols.

MOTS-c increases AICAR and activates AMPK, which leads to the upregulation of glucose transporter type 4 (GLUT4) expression in muscle cells. GLUT4 is responsible for glucose uptake in skeletal muscle and adipose tissues. The result is improved glucose disposal without requiring insulin signalling to initiate it — a mechanism of significant interest in insulin resistance and type 2 diabetes research models.

Nuclear translocation and adaptive gene expression

MOTS-c promotes metabolic homeostasis in part via AMPK and by directly regulating adaptive nuclear gene expression following nuclear translocation. When MOTS-c enters the nucleus under stress or exercise conditions, it binds to antioxidant response elements (ARE) and upregulates genes involved in stress resistance, oxidative defence, and metabolic adaptation. This retrograde communication — mitochondria issuing instructions to the nucleus — represents a fundamentally different regulatory architecture than conventional hormone-receptor systems.

Insulin sensitivity and GLUT4 upregulation

MOTS-c treatment induces activation of the AMPK signalling pathway, which improves insulin sensitivity and upregulates GLUT4 expression in skeletal muscle, enabling efficient glucose uptake and metabolism. In high-fat diet rodent models, MOTS-c treatment prevented obesity and hyperinsulinemia by regulating GLUT4 in an AMPK-dependent manner — making it one of the most mechanistically specific compounds in insulin resistance research.

Mitochondrial biogenesis

MOTS-c increases mitochondrial biogenesis biomarkers through activation of the AMPK pathway, preserving mitochondrial structure in treated subjects. This property is relevant for exercise physiology research — MOTS-c appears to replicate some of the mitochondrial adaptations that occur with endurance training at the cellular level, which is why it is consistently described in the research literature as an exercise mimetic.

Anti-inflammatory and neuroprotective effects

Beyond metabolic regulation, MOTS-c has gradually been found to affect obesity, inflammation, neuroprotection, and aging-induced hypokinesia — potentially contributing to healthy aging. Its anti-inflammatory activity operates downstream of AMPK activation, which suppresses NF-κB-mediated inflammatory gene transcription — a mechanism that overlaps with its metabolic effects and positions MOTS-c as relevant for inflammatory disease research beyond pure metabolic contexts.

Research Evidence

Insulin resistance and type 2 diabetes

The most extensive preclinical evidence base for MOTS-c concerns insulin resistance and glucose dysregulation. Systemic MOTS-c treatment reversed diet-induced obesity and diet- and age-dependent insulin resistance in mice. Multiple independent rodent studies across type 1, type 2, and gestational diabetes models have shown MOTS-c treatment lowering blood glucose levels, improving glucose handling, and restoring insulin sensitivity — consistently through AMPK-GLUT4 pathway activation in skeletal muscle.

MOTS-c treatment decreased fasted blood glucose levels and improved glucose handling in type 2 diabetic rats. An 8% decrease in left ventricular wall thickness was observed in the treated diabetic group, highlighting potential beneficial effects on cardiac dysfunction. The cardiac finding is significant — it extends MOTS-c’s research relevance from metabolic to cardiovascular applications in diabetic disease models.

The 2026 human clinical trial — NCT07505745

This is the most important current development in MOTS-c research. NCT07505745 is actively testing whether 12 weeks of MOTS-c improves OGTT-derived insulin sensitivity versus placebo in adults with prediabetes and overweight or obesity. The trial excludes recent use of glucose-lowering medications including metformin, GLP-1 receptor agonists, and SGLT2 inhibitors to keep the metabolic signal clean. Key endpoints include insulin sensitivity, HbA1c, fasting glucose, 2-hour OGTT glucose, body weight, and waist circumference.

This is the first human trial of MOTS-c at this scale and represents a pivotal moment for the compound’s research trajectory. Results will determine whether the strong preclinical evidence base translates to human metabolic outcomes.

Exercise physiology and physical performance

MOTS-c functions as a mitochondrial-encoded regulator of physical capacity and performance, with studies conducted in young, middle-aged, and old mice. In aged rodent models, exogenous MOTS-c partially restored metabolic and physical performance parameters toward those seen in younger animals — a finding that has driven considerable interest from exercise physiology and longevity researchers. The compound’s exercise-inducible expression and its ability to replicate some metabolic adaptations of endurance training at the cellular level have led researchers to study it alongside conventional exercise protocols.

Bone biology and osteoporosis

MOTS-c has demonstrated activity in bone metabolism research — one of the specific applications under FDA PCAC review in July 2026. Studies have examined its effects on bone mineral density and osteoclast activity, with findings suggesting protective effects in age-related bone loss models through AMPK-mediated pathways.

Cardiac research

MOTS-c treatment restored mitochondrial respiration in the type 2 diabetic heart and preserved mitochondrial structure, with increases in both citrate synthase activity and mitochondrial number in treated diabetic groups. The cardiac research dimension is an emerging application area separate from the primary metabolic work — particularly relevant for labs studying the cardiovascular complications of metabolic disease. nih

Dosing Protocols — Preclinical Research Reference

⚠️ The following is drawn from published animal studies and preclinical research protocols. The first human trial is currently underway (NCT07505745) but results are pending. No established human dosing protocol exists. This is provided for research planning and educational reference only. PeptideNexusLab does not recommend or endorse human self-administration.

Subcutaneous injection (standard metabolic research protocol)

Research dose range: 0.5–5 mg/kg in rodent models Frequency: Once daily or three times per week in most published protocols Cycle length: 4–12 weeks in the most referenced metabolic studies Primary research applications: Insulin resistance, obesity, glucose homeostasis, exercise adaptation

Intraperitoneal injection (rodent models)

Used interchangeably with subcutaneous in many published protocols. Research dose range: 0.5–5 mg/kg Notes: IP administration is common in the older MOTS-c literature; more recent protocols favour subcutaneous for translational relevance.

Human trial reference dose

Cash-pay costs at compounding pharmacies currently run $200 to $500 per month at common therapeutic doses being studied. Specific doses used in NCT07505745 have not been publicly disclosed pending trial completion.

Reconstitution Guide

What you need

Step-by-step reconstitution

Step 1 — Remove the MOTS-c vial from cold storage 10–15 minutes before starting. Allow it to reach room temperature naturally.

Step 2 — Wipe the rubber stopper with a 70% IPA swab. Wait 30 seconds to dry fully. Repeat every time you access the vial.

Step 3 — Draw your target BAC water volume into the syringe. Inject slowly down the inner glass wall — not directly onto the powder. Prevents foaming and mechanical degradation.

Step 4 — Swirl gently between your palms for 2–3 minutes. Do not shake. Swirl until completely clear and uniform with no visible particles.

Step 5 — Inspect. Clear to slightly pale is expected. Cloudy or particulate — discard immediately.

Step 6 — Label with date and concentration. Refrigerate immediately at 2–8°C. Use within 28 days. Protect from light.

Standard concentration reference

Add 1 mL bacteriostatic water to a 5 mg vial → 5,000 mcg/mL solution. Add 2 mL to a 10 mg vial → same 5,000 mcg/mL concentration. A 500 mcg research dose = 0.10 mL = 10 units on a U-100 insulin syringe.

MOTS-c Stacking Protocols

MOTS-c + Semaglutide — metabolic research stack

GLP-1-based drugs primarily target incretin and appetite pathways. MOTS-c is being studied as a mitochondrial-derived peptide tied to energy sensing, skeletal muscle glucose metabolism, and AMPK-related signalling. These are non-overlapping mechanisms — Semaglutide works from the gut-brain axis and appetite side; MOTS-c works from the mitochondrial-skeletal muscle side. In research protocols studying comprehensive metabolic intervention, the two are studied together for additive coverage.

MOTS-c + MK-677 — longevity and body composition stack

MK-677 (Ibutamoren) stimulates growth hormone secretion via ghrelin receptor activation. MOTS-c drives mitochondrial biogenesis and metabolic efficiency through AMPK. Combined, this stack is studied for body composition research — particularly in aging models where both GH axis decline and mitochondrial dysfunction contribute to loss of lean mass and metabolic flexibility.

MOTS-c + Tesamorelin — metabolic and body composition stack

Tesamorelin’s GH-releasing properties combined with MOTS-c’s AMPK-driven glucose and fatty acid metabolism creates a complementary two-mechanism approach for visceral adiposity and metabolic health research — particularly relevant for models studying age-related metabolic deterioration.

MOTS-c alone — exercise physiology and longevity protocols

In exercise physiology research, MOTS-c is frequently studied as a standalone compound to isolate its exercise-mimetic effects — specifically whether it can replicate AMPK-driven mitochondrial adaptations in sedentary aged animal models independent of actual exercise.

MOTS-c vs Comparator Compounds

Storage Guide

Vial Specifications

2026 Regulatory Update

FDA PCAC review — July 2026: The FDA’s Pharmacy Compounding Advisory Committee is reviewing MOTS-c for the Section 503A Bulk Drug Substances List in July 2026, with obesity and osteoporosis as the specific uses under evaluation. A positive outcome would give clinicians and compounding pharmacies clear regulatory standing. A negative outcome would likely restrict legal compounding of MOTS-c under Section 503A. This is the most significant regulatory event for MOTS-c in 2026.

United States — Not FDA-approved for any indication. Available for qualified laboratory research use only pending the July 2026 PCAC review outcome.

United Kingdom — Not classified under the Misuse of Drugs Act 1971. Not licensed by the MHRA. Legal to purchase for bona fide laboratory research.

European Union — Not approved by the EMA. Research chemical status; human administration not approved.

Australia — Not listed on the ARTG. Research chemical status; TGA has not approved human use.

Canada — Not scheduled under the CDSA. Available for legitimate laboratory research.

WADA — Not currently listed on the WADA Prohibited List as of 2026. Athletes and researchers should monitor for updates.

Frequently Asked Questions

What is MOTS-c? MOTS-c is a 16-amino acid peptide encoded by mitochondrial DNA — not nuclear DNA like most proteins. It was discovered in 2015 and acts through the Folate-AICAR-AMPK pathway to regulate glucose metabolism, insulin sensitivity, mitochondrial biogenesis, and cellular stress response. Its levels decline with aging, making it a key compound in both metabolic disease and longevity research.

How does MOTS-c work? MOTS-c activates AMPK by inhibiting the de novo purine synthesis pathway, reducing methyleneTHF availability and driving AICAR accumulation. This triggers GLUT4 upregulation in skeletal muscle, improving glucose uptake. It also translocates to the nucleus to directly regulate stress-adaptive gene expression — a retrograde mitochondria-to-nucleus signalling mechanism not seen in conventional peptide hormones.

Is MOTS-c an exercise mimetic? In preclinical models, MOTS-c replicates some of the metabolic adaptations triggered by endurance exercise — specifically AMPK activation, GLUT4 upregulation, and mitochondrial biogenesis. However, exercise affects many systems that no single peptide can duplicate. Researchers studying exercise-mimetic compounds use MOTS-c to isolate the mitochondrial-AMPK component of exercise adaptation.

Is there human trial data for MOTS-c? A first large-scale human trial is underway. NCT07505745 is testing whether 12 weeks of MOTS-c improves OGTT-derived insulin sensitivity versus placebo in adults with prediabetes and overweight or obesity. Results are pending. This is the most significant human data development for MOTS-c to date.

How does MOTS-c compare to Semaglutide for metabolic research? They work through entirely different mechanisms. GLP-1-based drugs like Semaglutide primarily target incretin and appetite pathways. MOTS-c is tied to energy sensing, skeletal muscle glucose metabolism, and AMPK-related signalling. For researchers studying the full picture of metabolic intervention — rather than just GLP-1 pathway effects — MOTS-c addresses a distinct and complementary biological dimension.

What is MOTS-c’s FDA status in 2026? MOTS-c is scheduled for FDA PCAC review in July 2026 for obesity and osteoporosis applications under Section 503A. The outcome will determine whether it can be legally compounded. It currently has no FDA approval for any indication and is available for laboratory research use only.

What is the difference between MOTS-c and Humanin? Both are mitochondrial-derived peptides but address different biological functions. MOTS-c primarily regulates energy metabolism and insulin sensitivity through AMPK. Humanin is studied primarily for neuronal stress protection, apoptosis inhibition, and cellular stress response. They are complementary rather than redundant research tools.

Does MOTS-c decline with age? Yes. MOTS-c expression decreases with aging. Circulating MOTS-c levels in plasma decline measurably with chronological age, tracking alongside reduced mitochondrial function and worsening metabolic flexibility. This age-dependent decline is a central rationale for its study in longevity and healthy aging research.

References

1. Lee C, et al. (2015). MOTS-c: a mitochondrial-derived peptide regulating skeletal muscle and fat metabolism. Cell Metabolism, 21(3), 443–454.
2. Kim KH, et al. (2018). Mitochondrial-encoded MOTS-c is an exercise-induced regulator of aging metabolic homeostasis. bioRxiv.
3. NCT07505745 — Active human clinical trial: MOTS-c vs placebo in prediabetes, 12-week intervention.
4. Liu M, et al. (2025). MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Frontiers in Physiology.
5. Review: Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. PMC 9854231.

⚠️ Research Use Only: MOTS-c is intended strictly for qualified in vitro laboratory research by trained professionals. Not for human or animal consumption. Not evaluated or approved by the FDA, EMA, MHRA, or TGA. Purchasers confirm compliance with all applicable local regulations.